ClinicalTrials.gg
RecruitingNCT03132129PREDICTUpdated Jan 5, 2024

Prevalence and Determinants of Subclinical Cardiovascular Dysfunction in Adults With Type 2 Diabetes Mellitus

An observational study in Diabetes Mellitus, Type 2 and Diabetic Cardiomyopathies, sponsored by University of Leicester. Recruiting at 1 site in United Kingdom. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by University of Leicester · Observational

How we know

From the registry’s dates

  • Started Oct 2017; still recruiting 9 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
593
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Diabetes Mellitus, Type 2 by University of Leicester — 6 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 2 · University of Leicester.

Planned enrollment
4th of 11
593 · median 241
Started
2017
with 1 other
Observational
11 of 23
5 open now
Registered
10th of 23
by date

Among the 23 studies in Diabetes Mellitus, Type 2 by University of Leicester, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2017, is one of 11 observational ones, and was the 10th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 23 studies in Diabetes Mellitus, Type 2 by University of Leicester are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Diabetes Mellitus, Type 2 by University of Leicester, or all of them as a file.
02

Study summary

Background: Heart failure is a major cause of morbidity and mortality in diabetes mellitus, but its pathophysiology is poorly understood.

Aim: To determine the prevalence and determinants of subclinical cardiovascular dysfunction in adults with type 2 diabetes (T2D).

Plan: 518 asymptomatic adults (aged 18-75 years) with T2D will undergo comprehensive evaluation of cardiac structure and function using cardiac MRI (CMR) and spectroscopy, echocardiography, CT coronary calcium scoring, exercise tolerance testing and blood sampling. 75 controls will undergo the same evaluation.

Primary hypothesis: myocardial steatosis is an independent predictor of left ventricular global longitudinal strain. Secondary hypotheses: will assess whether CMR is more sensitive to detect early cardiac dysfunction than echocardiography and BNP, and whether cardiac dysfunction is related to peak oxygen consumption.

Expected value of results: This study will reveal the prevalence and determinants of cardiac dysfunction in T2D, and could provide targets for novel therapies.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Diabetic Cardiomyopathies

Keywords

  • Type 2 diabetes
  • Diabetic cardiomyopathy
  • Cardiovascular magnetic resonance
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Cases will be adults with stable type 2 diabetes and no past medical history of known cardiovascular disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is willing and able to give for participation in the study.
  • Male or Female, aged ≥18 and ≤75 years.
  • Diagnosed with Stable type 2 diabetes (determined by: i) formal diagnosis in GP case records, ii) a record of diagnostic oral glucose tolerance test OR level ≥6.5%).

Exclusion criteria

Exclusion Criteria:

  • Angina pectoris or limiting dyspnoea (> II),
  • Major atherosclerotic disease: Symptomatic CAD, history of myocardial infarction, previous revascularisation, stroke/ or symptomatic peripheral vascular disease.
  • Atrial fibrillation or flutter.
  • Moderate or severe valvular heart disease.
  • History of heart failure or cardiomyopathy.
  • Type 1 diabetes mellitus (T1DM).
  • Low fasting C-peptide levels suggestive of adult-onset T1DM.
  • Stage III-V renal disease (estimated ≤30ml/min/1.73m2).
  • Absolute to CMR.

Importantly, patients with subclinical CAD, and other common comorbidities such as obesity and hypertension, will not be excluded from this study. This will enable us to evaluate the contribution of CAD to myocardial dysfunction in diabetes and ensures our study group is representative of the general population with diabetes. Similarly, as mild dyspnoea is extremely common and non-specific participants with mild dyspnoea will be included.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
593 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Type 2 diabetics

    Participants will be aged (≥18 and ≤75 years) with T2D and no prior history of cardiovascular disease.

    Diagnostic Test: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy · Diagnostic Test: Transthoracic echocardiography · Diagnostic Test: Computed tomography coronary artery calcium scoring · Diagnostic Test: Cardiopulmonary exercise testing · Diagnostic Test: Manganese-enhanced magnetic resonance imaging (MEMRI) · Diagnostic Test: Ambulatory blood pressure monitoring · Diagnostic Test: Accelerometer watch · Diagnostic Test: Blood tests

  • Healthy controls

    Cases will be compared with age-, gender- and ethnicity-matched healthy controls.

    Diagnostic Test: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy · Diagnostic Test: Transthoracic echocardiography · Diagnostic Test: Computed tomography coronary artery calcium scoring · Diagnostic Test: Cardiopulmonary exercise testing · Diagnostic Test: Manganese-enhanced magnetic resonance imaging (MEMRI) · Diagnostic Test: Ambulatory blood pressure monitoring · Diagnostic Test: Accelerometer watch · Diagnostic Test: Blood tests

Interventions

  • Diagnostic testCardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy

    CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.

  • Diagnostic testTransthoracic echocardiography

    Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.

  • Diagnostic testComputed tomography coronary artery calcium scoring

    Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.

  • Diagnostic testCardiopulmonary exercise testing

    Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.

  • Diagnostic testManganese-enhanced magnetic resonance imaging (MEMRI)

    A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.

  • Diagnostic testAmbulatory blood pressure monitoring

    A 24-hour blood pressure monitor will be worn at the end of the visit to the following day.

  • Diagnostic testAccelerometer watch

    Watch worn to collect free living physical activity data for 7 days.

  • Diagnostic testBlood tests

    Collection of blood samples from each participant to characterise the participant's health status and to develop a proteomic signature of early heart failure.

06

What researchers measure

Primary outcomes

  1. Prevalence of early heart failure in type 2 diabetes

    Proportion of participants with type 2 diabetes who have features of early heart failure

    Time frame: 5 years

Secondary outcomes

  1. Multivariate and independent predictors of LV systolic and diastolic function in type 2 diabetes

    Multivariate and independent predictors of LV systolic and diastolic function in type 2 diabetes

    Time frame: 3 years

  2. Sensitivity of CMR versus echocardiography and BNP for detecting subclinical cardiovascular dysfunction in type 2 diabetes

    Sensitivity of CMR versus echocardiography and BNP for detecting subclinical cardiovascular dysfunction in type 2 diabetes

    Time frame: 3 years

  3. Independent association of CMR measures with aerobic exercise capacity in type 2 diabetes

    Independent association of CMR measures (LV systolic and diastolic strain and strain rates) with aerobic exercise capacity (peak VO2) in type 2 diabetes

    Time frame: 3 years

  4. Differences in LV remodelling (indexed LV mass) between cases and controls

    Differences in LV remodelling (indexed LV mass) between cases and controls

    Time frame: 3 years

  5. Independent clinical and imaging predictors of major adverse cardiovascular and, in particular, heart failure events in the patients with type 2 diabetes

    Independent clinical and imaging predictors of major adverse cardiovascular and, in particular, heart failure events in the patients with type 2 diabetes

    Time frame: 5 years

  6. Differences in cardiac MRI and echo-derived systolic and diastolic strain and strain rates between cases and controls.

    Differences in cardiac MRI and echo-derived systolic and diastolic strain and strain rates between cases and controls.

    Time frame: 3 years

  7. Differences in coronary atheroma burden (CT coronary artery calcium score) between cases and controls

    Differences in coronary atheroma burden (CT coronary artery calcium score) between cases and controls

    Time frame: 3 years

  8. Differences in aerobic exercise capacity (peak V02) between cases and controls

    Differences in aerobic exercise capacity (peak V02) between cases and controls

    Time frame: 3 years

  9. Differences in myocardial perfusion reserve between cases and controls

    Differences in myocardial perfusion reserve between cases and controls

    Time frame: 3 years

  10. Differences in heart rate and blood pressure variability between cases and controls

    Differences in heart rate and blood pressure variability between cases and controls

    Time frame: 3 years

  11. Myocardial steatosis

    Myocardial steatosis as an independent predictor of LV global longitudinal strain

    Time frame: 3 years

  12. Myocardial calcium handling as assessed by manganese-enhanced magnetic resonance imaging (MEMRI)

    Manganese influx constants calculated using Patlak modelling

    Time frame: 5 years

  13. Proteomic signature

    Proteomic analysis will be conducted to identify a proteomic signature of early heart failure in type 2 diabetes that will be externally validated

    Time frame: 5 years

  14. Remission of type 2 diabetes

    The phenotype of participants defined as in remission will be compared to active type 2 diabetes and healthy volunteers

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Yeo JL, Gulsin GS, Brady EM, Dattani A, Bilak JM, Marsh AM, Sian M, Athithan L, Parke KS, Wormleighton J, Graham-Brown MPM, Singh A, Arnold JR, Lawson C, Davies MJ, Xue H, Kellman P, McCann GP. Association of ambulatory blood pressure with coronary microvascular and cardiac dysfunction in asymptomatic type 2 diabetes. Cardiovasc Diabetol. 2022 May 28;21(1):85. doi: 10.1186/s12933-022-01528-2. PubMed 35643571 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2017 (actual). Primary completion is estimated for Oct 2029, 144 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2017
First posted
Apr 27, 2017
StartActual
Oct 24, 2017
Primary completionEst.
Oct 31, 2029
CompletionEst.
Oct 31, 2029
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03132129
Responsible party
Sponsor
First posted
Apr 27, 2017
Start date
Oct 24, 2017
Primary completion
Oct 31, 2029 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Jan 5, 2024

Study contacts

Gerry P McCann, MD
Contact
gpm12@le.ac.uk
01162583402
Gaurav S Gulsin, MBChB(Hons)
Contact
gg149@leicester.ac.uk
01162583244
Gerry P McCann, MD
principal investigator · University of Leicester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion